HC Wainwright Initiates Coverage on Alto Neuroscience (NYSE:ANRO)

HC Wainwright started coverage on shares of Alto Neuroscience (NYSE:ANRO - Get Free Report) in a report issued on Monday, MarketBeat.com reports. The firm set a "buy" rating and a $10.00 price target on the stock. HC Wainwright's price objective would suggest a potential upside of 373.26% from the company's current price. HC Wainwright also issued estimates for Alto Neuroscience's Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.32) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($3.04) EPS, FY2027 earnings at ($3.07) EPS, FY2028 earnings at ($2.99) EPS and FY2029 earnings at ($1.69) EPS.

Separately, William Blair reiterated an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.40.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO traded up $0.06 during midday trading on Monday, reaching $2.11. 168,333 shares of the company's stock were exchanged, compared to its average volume of 372,425. The firm has a market capitalization of $57.20 million, a PE ratio of -0.83 and a beta of 2.16. The company's 50 day simple moving average is $2.87 and its two-hundred day simple moving average is $4.84. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $17.55. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.09. Equities research analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

A number of large investors have recently modified their holdings of the business. Wellington Management Group LLP raised its stake in shares of Alto Neuroscience by 27.2% during the 4th quarter. Wellington Management Group LLP now owns 77,146 shares of the company's stock worth $326,000 after purchasing an additional 16,510 shares in the last quarter. AWM Investment Company Inc. raised its position in Alto Neuroscience by 22.9% during the fourth quarter. AWM Investment Company Inc. now owns 687,831 shares of the company's stock worth $2,910,000 after acquiring an additional 128,100 shares in the last quarter. Woodline Partners LP raised its position in Alto Neuroscience by 397.6% during the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company's stock worth $2,631,000 after acquiring an additional 496,976 shares in the last quarter. Vestal Point Capital LP lifted its stake in Alto Neuroscience by 40.8% in the fourth quarter. Vestal Point Capital LP now owns 915,000 shares of the company's stock valued at $3,870,000 after acquiring an additional 265,000 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Alto Neuroscience by 137.2% in the 4th quarter. Two Sigma Investments LP now owns 30,700 shares of the company's stock valued at $130,000 after acquiring an additional 17,760 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.